The New England Journal of Medicine has published results of the phase III teriflunomide trial (this center was not involved in this trial). Teriflunomide is a new oral medication developed to treat MS. The phase III data, in 1088 relapsing-remitting MS patients, is encouraging in that this medication showed a significant reduction in relapse rate and MRI endpoints over placebo (sugar pill). Importantly, the saftey profile of this drug is also encouraging. This drug is not yet been approved by the FDA and is currently not available.